ClinicalTrials.gg
Status unknownNCT04703374Updated Jan 11, 2021

A Study to Compare PK, PD and Safety of CKD-382 in Healthy Subjects

A Phase 1 interventional study of CKD-382(formulation I) and CKD-382(formulation II) in GERD, sponsored by Chong Kun Dang Pharmaceutical. Status unknown at 1 site in Korea, Republic of. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-11.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2021), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Sep 2020, registered Jan 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
19 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of — 8 open to participants now, 10 under way, none of them phase 3. Gastroesophageal Reflux · Korea, Republic of.

Planned enrollment
27th of 52
48 · median 54
Started
2020
with 4 others
Phase 1
21 of 71
2 open now
Registered
45th of 71
by date
Lead sponsor
9 of 71
Chong Kun Dang Pharmaceutical

Among the 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of, this one is the 27th largest by planned enrollment of the 52 interventional ones that give a count, is one of 5 that started in 2020, is one of 21 in phase 1, and was the 45th registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

8 of the 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 19 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of, or all of them as a file.
02

Study summary

To compare pharmacokinetics, pharmacodynamics and safety after single/multiple administration of CKD-382 and D026 in healthy subjects

Read the detailed description

A randomized, open-label, crossover phase 1 clinical trial to compare pharmacokinetics, pharmacodynamics and safety after single / multiple administration of CKD-382 and D026 in healthy subjects

03

Conditions studied

  • GERD

Keywords

  • CKD-382
  • D026
04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Between 19 aged and 50 aged in healthy adult
  2. Body weight more than 50kg
  3. more than 18.0 and under 27.0
  4. Who has negative result on Helicobacter Pylori antibody test

Exclusion criteria

Exclusion Criteria:

  1. Have disease that hepatobiliary system, kidney, nervous system, immune system, respiratory system, endocrine system, hemato-oncology disease, cardiovascular system or mental illness, or a history of mental disease.
  2. Have a gastrointestinal disease history(including surgery) that can effect drug absorption
  3. reaction or clinically significant hypersensitivity reaction in the history of Esomeprazole, additives or benzimidazole family.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    A

    Period 1: Test drug(CKD-382 formulation I) Period 2: Test drug(CKD-382 formulation II) Period 3: Reference drug(D026)

    Drug: CKD-382(formulation I) · Drug: CKD-382(formulation II) · Drug: D026

  • Experimental
    B

    Period 1: Test drug(CKD-382 formulation II) Period 2: Reference drug(D026) Period 3: Test drug(CKD-382 formulation I)

    Drug: CKD-382(formulation I) · Drug: CKD-382(formulation II) · Drug: D026

  • Experimental
    C

    Period 1: Reference drug(D026) Period 2: Test drug(CKD-382 formulation I) Period 3: Test drug(CKD-382 formulation II)

    Drug: CKD-382(formulation I) · Drug: CKD-382(formulation II) · Drug: D026

  • Experimental
    D

    Period 1: Test drug(CKD-382 formulation I) Period 2: Reference drug(D026) Period 3: Test drug(CKD-382 formulation II)

    Drug: CKD-382(formulation I) · Drug: CKD-382(formulation II) · Drug: D026

  • Experimental
    E

    Period 1: Test drug(CKD-382 formulation II) Period 2: Test drug(CKD-382 formulation I) Period 3: Reference drug(D026)

    Drug: CKD-382(formulation I) · Drug: CKD-382(formulation II) · Drug: D026

  • Experimental
    F

    Period 1: Reference drug(D026) Period 2: Test drug(CKD-382 formulation II) Period 3: Test drug(CKD-382 formulation I)

    Drug: CKD-382(formulation I) · Drug: CKD-382(formulation II) · Drug: D026

Interventions

  • DrugCKD-382(formulation I)

    1 tablet administered under fasting condition for 7days

  • DrugCKD-382(formulation II)

    1 tablet administered under fasting condition for 7days

  • DrugD026

    1 tablet administered under fasting condition for 7days

06

What researchers measure

Primary outcomes

  1. AUCtau,ss(Area under the plasma drug concentration-time curve within a dosing interval at steady state) Evaluation PK after multiple dose

    Time frame: 0~24h

  2. Percent decrease from baseline in integrated gastric acidity for 24-hour interval after 7th dose Evaluation PD for ambulatory 24hr pH monitor

    Time frame: Baseline versus Multiple dose during 7 days

07

Study locations

1 of 1 sites recruiting
  • Chungbuk National University Hospital
    Cheongju-si, Chungcheongbuk-do, Korea, Republic of
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2020 (actual). Primary completion is estimated for Sep 2021, 12 months after the start.

Of 28 industry-sponsored phase 1 interventional studies under Gastroesophageal Reflux, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 6. This study's planned 12 months is above that.

Counting every sponsor, half of 34 studies reached it within 4 months; a quarter within 2 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2021
First posted
Jan 11, 2021
StartActual
Sep 25, 2020
Primary completionEst.
Sep 2021
CompletionEst.
Sep 2021
Last update
Jan 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04703374
Responsible party
Sponsor
First posted
Jan 11, 2021
Start date
Sep 25, 2020
Primary completion
Sep 2021 (estimated)
Completion
Sep 2021 (estimated)
Last update
Jan 11, 2021

Study contacts

MinKyu Park, Ph.D
Contact
mk_park@cbnuhctc.com
043-269-8708

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion